Expression of p68 protein kinase and its prognostic significance during IFN-α therapy in patients with carcinoid tumours

European Journal of Cancer

Volumn 34, Issue 13, 1998, Pages 2046-2052

  Zhou, Y ^a   Gobi, A ^a   Wang, S ^a   Jacobsen, M B ^b   Janson, E T ^a   Haines III, G K ^c   Radosevich, J A ^c   Oberg, K ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Carcinoid; Interferon alpha; Neuroendocrione tumours; P68; PKR; Prognostic factor; Proliferation; Protein kinase

Indexed keywords

PROTEIN KINASE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOID; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEUROENDOCRINE TUMOR; NORTHERN BLOTTING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM;

ANTINEOPLASTIC AGENTS; CARCINOID TUMOR; CELL DIVISION; COLONIC NEOPLASMS; DEAD-BOX RNA HELICASES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON ALFA-2B; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTEIN KINASES; RETROSPECTIVE STUDIES; RNA HELICASES; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0032403822     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00292-5     Document Type: Article

References (42)

1. 1. Uze G, Lutfalla G, Mogensen KE. Alpha and beta interferons and their receptor and their friends and relations. J Interferon Cytokine Res 1995, 15, 3-26.
2. 2. Hovanessian AG. Interferon-induced and double-stranded RNA-activated enzymes: a specific protein kinase and 2′,5′-oligoadenylate synthetases. J Interferon Res 1991, 11, 199-205.
3. 3. Samuel CE. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991, 183, 1-11.
4. 4. Lengyel P. Tumor-suppressor genes: news about the interferon connection. Proc Natl Acad Sci USA 1993, 90, 5893-5895.
5. 5. Hovanessian AG. The double stranded RNA-activated protein kinase induced by interferon: dsRNA-PK. J Interferon Res 1989, 9, 641-647.
6. 6. Grander D, Oberg K., Lundqvist ML, et al. Interferon-induced enhancement of 2′,5′-oligoadenylate synthetase in mid-gut carcinoid tumours [see comments]. Lancet 1990, 336, 337-340.
7. 7. Sen GC, Lengyel P. The interferon system. A bird's eye view of its biochemistry. J Biol Chem 1992, 267, 5017-5020.
8. 8. Taylor JL, Samuel CE, Grossberg SE. Antiviral and anti-differentiative activities of interferon beta and gamma in relation to their induction of double-stranded RNA-dependent protein kinase activity in 3T3-L1 cells. J Biol Chem 1988, 263, 1336-1341.
9. 9. Oberg K. The action of interferon alpha on human carcinoid tumours. [Review]. Semin Cancer Biol 1988, 3, 35-41.
10. 10. Lee SB, Melkova Z, Yan W, Williams BR, Hovanessian AG, Esteban M. The interferon-induced double-stranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells. Virology 1993, 192, 380-385.
11. 11. Williams BR. Signal transduction and transcriptional regulation of interferon-alpha-stimulated genes. J Interferon Cytokine Res 1991, 11, 207-213.
12. 12. Koromilas AE, Roy S, Barber GN, Katze MG, Sonenberg N. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 1992, 257, 1685-1689.
13. 13. Lee SB, Esteban M. The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis. Virology 1994, 199, 491-496.
14. 14. Barber GN, Wambach M, Wong ML, Dever TE, Hinnebusch AG, Katze MG. Translational regulation by the interferon-induced double-stranded-RNA-activated 68-kDa protein kinase. Proc Natl Acad Sci USA 1993, 90, 4621-4625.
15. 15. Haines GK, Ghadge G, Thimmappaya B, Radosevich JA. Expression of the protein kinase p-68 recognized by the monoclonal antibody TJ4C4 in human lung neoplasms. Virchows Arch B Cell Pathol Incl Mol Pathol 1992, 62, 151-158.
16. 16. Haines GK, Becker S, Ghadge G, Kies M, Pelzer H, Radosevich JA. Expression of the double-stranded RNA-dependent protein kinase (p68) in squamous cell carcinoma of the head and neck region. Arch Otolaryngol Head Neck Surg 1993, 119, 1142-1147.
17. 17. Haines GK, Ghadge GD, Becker S, et al. Correlation of the expression of double-stranded RNA-dependent protein kinase (p68) with differentiation in head and neck squamous cell carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol 1993, 63, 289-295.
18. 18. Haines GK, Ghadge G, Radosevich JA. Expression of p68 protein kinase as recognized by the monoclonal antibody TJ4C4 during human fetal development. Tumour Biol 1993, 14, 95-104.
19. 19. Singh C, Haines GK, Talamonti MS, Radosevich JA. Expression of p68 in human colon cancer. Tumour Biol 1995, 16, 281-289.
20. 20. Wood JN, Hovanessian AG. Interferon enhances 2-5A synthetase in embryonal carcinoma cells. Nature 1979, 282, 74-76.
21. 21. Meurs EF, Galabru J, Barber GN, Katze MG, Hovanessian AG. Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 1993, 90, 232-236.
22. 22. Bajetta E, Di BM, Zilembo N, Bochicchio AM. Medical treatment of neuroendocrine tumors. Tumori 1993, 79, 380-388.
23. 23. Oberg K. Chemotherapy and biotherapy in neuroendocrine tumors [Review]. Current Opinion in Oncology 1993, 5, 110-120.
24. 24. Elvin A, Oberg K, Lindgren PG, et al. Interferon treatment of neuroendocrine tumour xenografts as monitored by MRI. Acta Oncologica 1994, 33, 567-571.
25. 25. Buer J, Kirchner H, Schomburg A, et al. Cytokine-based biotherapy of gastrointestinal tumors. Clin Invest 1994, 72, 526-534.
26. 26. Jacobsen MB, Hanssen LE, Kolmannskog F, Schrumpf E, Vatn MH, Bergan A. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scand J Gastroenterol 1995, 30, 789-796.
27. 27. Chaudhry A, Oberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biology 1992, 13, 27-35.
28. 28. Waltenberger J, Lundin L, Oberg K, et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Path 1993, 142, 71-78.
29. 29. Stridsberg M, Hellman U, Wilander E, Lundqvist G, Hellsing K, Oberg K. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993, 139, 329-237.
30. 30. Stridsberg M, Lundqvist G, Engstrom U, et al. Development of polyclonal antibodies and evaluation of a sensitive radioimmunoassay for detection and measurement of synaptophysin. Acta Neuropathologica 1994, 87, 635-641.
31. 31. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995, 144, 49-59.
32. 32. Stridsberg M, Eriksson B, Lundqvist G, Skogseid B, Wilander E, Oberg K. Islet amyloid polypeptide (LAPP) in patients with neuroendocrine tumours. Regulatory Peptides 1995, 55, 119-131.
33. 33. Evers BM, Ishizuka J, Townsend CJ, Thompson JC. The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann NY Acad Sci 1994, 733, 393-406.
34. 34. Lundqvist M, Mark J, Funa K, et al. Characterisation of a cell line (LCC-18) from a cultured human neuroendocrine-differentiated colonic carcinoma. Eur J Cancer 1991, 27, 1663-1668.
35. 35. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162, 156-159.
36. 36. Meurs E, Chong K, Galabru J, et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990, 62, 379-390.
37. 37. Tiensuu JE, Ahlstrom H, Andersson T, Oberg K. Octretide and interferon alpha: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992, 28A, 1647-1650.
38. 38. Hsu DW, Efird JT, Hedley WE. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 1995, 147, 114-123.
39. 39. Oberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment [Review]. Anti Cancer Drugs 1994, 5, 503-519.
40. 40. Oberg K, Eriksson B, Janson ET. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors [Review]. Digestion 1994, 3, 64-69.
41. 41. Janson ET, Ronnblom L, Ahlstrom H, et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 1992, 3, 635-638.
42. 42. Buffet JC, Vannier JP, Laurent AG, Robert N, Hovanessian AG. Enhanced level of double-stranded RNA-dependent protein kinase in peripheral blood mononuclear cells of patients with viral infections. J Interferon Res 1986, 6, 85-96.